Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells
Malignant pleural mesothelioma (MPM) is a rare type of cancer with a grim prognosis. So far, no targetable oncogenic mutation was identified in MPM and biomarkers with predictive value toward drug sensitivity or resistance are also lacking. Nintedanib (BIBF1120) is a small-molecule tyrosine kinase i...
Main Authors: | Luca Hegedüs, Kata D. Szücs, Matthias Kudla, Julian Heidenreich, Verena Jendrossek, Samuel Peña-Llopis, Tamas Garay, Andras Czirok, Clemens Aigner, Till Plönes, Silvia Vega-Rubin-de-Celis, Balazs Hegedüs |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.852812/full |
Similar Items
-
Nintedanib treatment for bleomycin-induced lung injury - First report
by: Dina Rnjak, et al.
Published: (2023-01-01) -
A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
by: Nicolas Bradt, et al.
Published: (2022-10-01) -
Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01) -
Dasatinib-Related Chylothorax
by: Yen Min Huang, et al.
Published: (2015-02-01) -
Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01)